US Pharma MarketingThe post Corcept’s ALS drug demonstrates two-year benefit despite primary endpoint miss appeared first on Clinical Trials Arena.
Corcept’s ALS drug demonstrates two-year benefit despite primary endpoint miss
After two years, there was an 87% reduction in death in ALS patients treated with Corcept's dazucorilant compared with those who received placebo. After two years of treatment, there was an 87% reduction in death in treated patients compared with those who received placebo. Corcept is now looking to advance the ALS drug to Phase III trials. Credit: Faizal Ramli / Shutterstock.com Corcept Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has shown two-year survival benefit above placebo, despite the trial having failed to achieve its primary endpoint. In the Phase II DAZALS study (NCT05407324), ALS patients who received 300mg dazucorilant, a…
After two years, there was an 87% reduction in death in ALS patients treated with Corcept's dazucorilant compared with those who received placebo.
Source: Clinical Trials Arena